NanoViricides, Inc. (NYSE American: NNVC) is drawing attention to its broad-spectrum antiviral candidate NV-387 in light of the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The clinical-stage antiviral drug developer stated that NV-387, if proven effective against the virus strain, could offer a differentiated approach to treating Ebola. The company emphasized the drug's proposed mechanism, which targets viral cell attachment pathways common across filoviruses, positioning the candidate as a potential tool for pandemic preparedness against Ebola and related viral threats.
NV-387 is NanoViricides' lead drug candidate, developed as a broad-spectrum antiviral for respiratory infections such as RSV, COVID-19, Long COVID, influenza, as well as MPOX, smallpox, and measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials. In the context of the Ebola outbreak, NanoViricides highlighted that NV-387's oral formulation could be a significant advantage in resource-limited settings, where injectable treatments may be less accessible.
The company's platform technology, based on TheraCour nanomedicine, aims to create special purpose nanomaterials for antiviral therapy. NanoViricides holds a worldwide exclusive perpetual license for several drug applications, including for Ebola and Marburg viruses. The company noted that its nanoviricide technology targets viruses by mimicking host cell receptors, thereby binding to and neutralizing the virus before it can infect cells.
NanoViricides' business model relies on licensing technology from TheraCour Pharma, Inc. for specific virus applications. The company has developed both NV-CoV-2 and NV-CoV-2-R independently, with the latter encapsulating remdesivir. While the company believes that NV-CoV-2-R could be an approvable drug given remdesivir's FDA approval, it cautioned that no assurance can be given at this time regarding the effectiveness or safety of any of its candidates in human clinical development.
Investors can view the full press release at https://ibn.fm/mm3Z5. For more information about NanoViricides, visit www.nanoviricides.com.
